Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$0.06
-14.5%
$0.17
$0.05
$1.32
$15.61M2.1813.62 million shs40.17 million shs
DURECT Corporation stock logo
DRRX
DURECT
$1.92
-1.0%
$1.20
$0.48
$2.64
$59.62M0.83458,118 shs209,605 shs
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$4.90
-2.4%
$4.66
$3.61
$11.09
$57.76M1.52317,550 shs41,892 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$9.70
$9.89
$8.50
$23.00
$60.64MN/A37,647 shs331 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
+15.41%+17.78%-34.32%-74.00%-94.35%
DURECT Corporation stock logo
DRRX
DURECT
+0.52%+2.11%+3.19%+252.92%+39.57%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
+0.20%+5.91%+2.66%+3.29%-48.35%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
+4.19%-0.82%-2.81%-30.22%+969,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
1.874 of 5 stars
3.03.00.00.02.31.70.0
DURECT Corporation stock logo
DRRX
DURECT
1.6459 of 5 stars
0.05.00.04.42.70.00.0
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.0001 of 5 stars
3.51.00.04.62.71.70.6
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
2.00
Hold$1.352,194.85% Upside
DURECT Corporation stock logo
DRRX
DURECT
2.00
HoldN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
3.00
Buy$47.00859.18% Upside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ADAP, DRRX, DTIL, and IZTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
7/29/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
7/29/2025
DURECT Corporation stock logo
DRRX
DURECT
Northland Capmk
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/26/2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$1.50 ➝ $0.50
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
$178.03M0.09N/AN/A($0.27) per share-0.22
DURECT Corporation stock logo
DRRX
DURECT
$2.03M29.37N/AN/A$0.11 per share17.45
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$1.26M45.80N/AN/A$2.89 per share1.70
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$70.81M-$0.65N/AN/AN/A-260.82%-163.73%-75.83%11/12/2025 (Estimated)
DURECT Corporation stock logo
DRRX
DURECT
-$8.32M-$0.10N/AN/AN/A-96.19%-259.16%-71.78%11/12/2025 (Estimated)
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/A0.00N/AN/AN/AN/AN/A

Latest ADAP, DRRX, DTIL, and IZTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
-$0.15-$0.11+$0.04-$0.11$11.04 million$13.68 million
8/12/2025Q2 2025
DURECT Corporation stock logo
DRRX
DURECT
-$0.13-$0.07+$0.06-$0.07$0.32 million$0.45 million
8/7/2025Q2 2025
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
N/AN/AN/AN/AN/A
DURECT Corporation stock logo
DRRX
DURECT
N/AN/AN/AN/AN/A
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
4.24
1.52
1.29
DURECT Corporation stock logo
DRRX
DURECT
N/A
0.98
0.95
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
0.66
5.18
5.18
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
31.37%
DURECT Corporation stock logo
DRRX
DURECT
28.03%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
37.99%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
12.74%
DURECT Corporation stock logo
DRRX
DURECT
3.20%
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
4.50%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Adaptimmune Therapeutics PLC stock logo
ADAP
Adaptimmune Therapeutics
490265.05 million231.28 millionOptionable
DURECT Corporation stock logo
DRRX
DURECT
8031.05 million30.06 millionOptionable
Precision BioSciences, Inc. stock logo
DTIL
Precision BioSciences
20011.79 million11.26 millionNo Data
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Adaptimmune Therapeutics stock logo

Adaptimmune Therapeutics NASDAQ:ADAP

$0.06 -0.01 (-14.51%)
Closing price 04:00 PM Eastern
Extended Trading
$0.06 +0.00 (+1.87%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

DURECT stock logo

DURECT NASDAQ:DRRX

$1.92 -0.02 (-1.03%)
As of 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Precision BioSciences stock logo

Precision BioSciences NASDAQ:DTIL

$4.90 -0.12 (-2.39%)
Closing price 04:00 PM Eastern
Extended Trading
$4.88 -0.02 (-0.41%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$9.70 0.00 (0.00%)
As of 08/28/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.